1.55
+0.025(+1.64%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.53 |
| Day High | 1.58 |
| Day Low | 1.48 |
| 52-Week High | 5.01 |
| 52-Week Low | 1 |
| Volume | 106,985 |
| Average Volume | 1.89M |
| Market Cap | 47.97M |
| PE | -0.78 |
| EPS | -1.97 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 1.75 |
| Change | 0.03 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $87.83 as of March 13, 2025 at a share price of $1.545. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $228.89 as of March 13, 2025 at a share price of $1.545.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
GlobeNewswire Inc.
Feb 06, 2025 12:00 PM GMT
- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination wit
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 03, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced th
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Ne